Byrne Asset Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,227 shares of the company’s stock after buying an additional 130 shares during the period. Johnson & Johnson comprises 2.4% of Byrne Asset Management LLC’s investment portfolio, making the stock its 5th largest position. Byrne Asset Management LLC’s holdings in Johnson & Johnson were worth $3,679,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $4,609,399,000. Providence Capital Advisors LLC lifted its position in shares of Johnson & Johnson by 141,974.0% during the first quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock worth $30,651,000 after purchasing an additional 4,747,612 shares in the last quarter. Morgan Stanley raised its holdings in Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in Johnson & Johnson by 1.4% in the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock valued at $31,231,193,000 after acquiring an additional 2,688,798 shares in the last quarter. 68.40% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Johnson & Johnson
In related news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.
Johnson & Johnson Stock Down 0.1 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.59 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were given a $1.19 dividend. The ex-dividend date was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the stock. HSBC assumed coverage on shares of Johnson & Johnson in a report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price target on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Morgan Stanley cut their price target on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a report on Thursday, August 31st. Finally, Barclays lowered their target price on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a research note on Friday, September 8th. Nine equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $171.06.
Check Out Our Latest Stock Report on JNJ
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- How to Calculate Options Profits
- 5 Reasons Gilead Sciences is a Better Buy Than You Think
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Jobs Are Going To The Construction Industry, Momentum Play Time
- The Significance of Brokerage Rankings in Stock Selection
- PepsiCo Q3 Strength Results In A Trend Following Buy Signal
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
